Eli Lilly and Company (NYSE:LLY) Receives Consensus Recommendation of “Buy” from Analysts

Eli Lilly and Company (NYSE:LLYGet Rating) has been given an average rating of “Buy” by the twenty analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $304.83.

A number of brokerages have recently commented on LLY. Daiwa Capital Markets initiated coverage on shares of Eli Lilly and in a report on Thursday, March 10th. They issued an “outperform” rating and a $286.00 target price on the stock. Wells Fargo & Company lifted their target price on shares of Eli Lilly and from $280.00 to $305.00 in a research note on Friday, April 29th. The Goldman Sachs Group lifted their price target on shares of Eli Lilly and from $234.00 to $264.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. SVB Leerink began coverage on Eli Lilly and in a report on Monday. They set an “outperform” rating and a $341.00 target price on the stock. Finally, Morgan Stanley raised their target price on Eli Lilly and from $364.00 to $369.00 in a report on Friday, April 29th.

LLY stock traded up $3.98 during mid-day trading on Friday, hitting $317.44. 42,593 shares of the company were exchanged, compared to its average volume of 2,934,540. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 1.60. The firm has a market capitalization of $301.62 billion, a P/E ratio of 46.96, a PEG ratio of 2.27 and a beta of 0.40. The business has a fifty day simple moving average of $294.44 and a 200-day simple moving average of $269.04. Eli Lilly and has a 12-month low of $195.50 and a 12-month high of $314.00.

Eli Lilly and (NYSE:LLYGet Rating) last posted its quarterly earnings data on Thursday, April 28th. The company reported $2.62 EPS for the quarter, beating the consensus estimate of $2.32 by $0.30. Eli Lilly and had a net margin of 20.90% and a return on equity of 97.58%. The business had revenue of $7.81 billion during the quarter, compared to analyst estimates of $7.29 billion. During the same quarter last year, the firm posted $1.87 earnings per share. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. Research analysts predict that Eli Lilly and will post 8.25 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 10th. Shareholders of record on Monday, May 16th will be paid a dividend of $0.98 per share. The ex-dividend date of this dividend is Friday, May 13th. This represents a $3.92 dividend on an annualized basis and a yield of 1.23%. Eli Lilly and’s dividend payout ratio is currently 58.07%.

In other news, major shareholder Lilly Endowment Inc sold 20,018 shares of Eli Lilly and stock in a transaction on Wednesday, March 9th. The shares were sold at an average price of $266.52, for a total transaction of $5,335,197.36. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Marschall S. Runge purchased 202 shares of Eli Lilly and stock in a transaction dated Tuesday, March 1st. The shares were purchased at an average cost of $246.78 per share, for a total transaction of $49,849.56. The disclosure for this purchase can be found here. Insiders have sold 1,327,818 shares of company stock worth $380,782,218 in the last quarter. Corporate insiders own 0.12% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Cordant Inc. bought a new position in shares of Eli Lilly and during the first quarter worth $25,000. Wagner Wealth Management LLC boosted its position in shares of Eli Lilly and by 59.4% during the third quarter. Wagner Wealth Management LLC now owns 110 shares of the company’s stock worth $28,000 after purchasing an additional 41 shares in the last quarter. AllSquare Wealth Management LLC bought a new stake in Eli Lilly and in the 4th quarter valued at $28,000. HWG Holdings LP bought a new stake in Eli Lilly and in the 4th quarter valued at $28,000. Finally, Icapital Wealth LLC bought a new stake in Eli Lilly and in the 1st quarter valued at $28,000. 82.75% of the stock is currently owned by institutional investors.

About Eli Lilly and (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Articles

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.